Published in Ann Rheum Dis on January 27, 2005
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol (2007) 1.85
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol (2011) 1.59
New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol (2009) 1.35
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis (2013) 1.32
Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PLoS Med (2006) 1.31
Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis (2011) 1.19
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J (2007) 1.19
Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther (2011) 1.17
Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice. Br J Dermatol (2011) 1.17
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther (2009) 1.15
Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res (Hoboken) (2010) 1.09
Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis (2005) 1.05
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis (2006) 1.05
Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J (2013) 1.02
The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis (2007) 1.00
Infliximab: 12 years of experience. Arthritis Res Ther (2011) 0.99
Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS One (2012) 0.95
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res (2007) 0.94
Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis. Arthritis Res Ther (2013) 0.93
The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther (2007) 0.92
Psoriatic arthritis: an update. Arthritis (2012) 0.92
Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis (2006) 0.90
Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2010) 0.88
Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol (2011) 0.86
Adalimumab in the treatment of arthritis. Ther Clin Risk Manag (2007) 0.86
Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis. Biologics (2012) 0.84
Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open (2015) 0.83
Treatment of severe psoriasis with infliximab. Ther Clin Risk Manag (2008) 0.82
Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. Respir Res (2012) 0.81
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. Biologics (2008) 0.80
Infliximab (Remicade) in the treatment of psoriatic arthritis. Ther Clin Risk Manag (2006) 0.80
Altered bone biology in psoriatic arthritis. Curr Rheumatol Rep (2012) 0.80
Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study. Arthritis Res Ther (2012) 0.80
Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis (2013) 0.79
Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet Disord (2014) 0.79
Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment. J Immune Based Ther Vaccines (2005) 0.78
Infliximab in the treatment of plaque type psoriasis. Clin Cosmet Investig Dermatol (2009) 0.78
Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation. Arthritis Res Ther (2014) 0.78
Classification and categorisation of psoriatic arthritis. Clin Rheumatol (2008) 0.78
Spondyloarthritides: evolving therapies. Arthritis Res Ther (2010) 0.77
Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis. Clin Rheumatol (2016) 0.77
Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int (2014) 0.77
Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ (2011) 0.77
The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project. Clin Rheumatol (2009) 0.77
A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors. Ann Rheum Dis (2006) 0.77
Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Clin Rheumatol (2011) 0.77
Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open (2015) 0.77
Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience. Ann Rheum Dis (2006) 0.76
Psoriatic arthritis: latest treatments and their place in therapy. Ther Adv Chronic Dis (2015) 0.76
Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis. Clin Cosmet Investig Dermatol (2010) 0.76
Making the next steps in psoriatic arthritis management: current status and future directions. Ther Adv Musculoskelet Dis (2015) 0.76
Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment. Arthritis Rheumatol (2016) 0.76
Management of ankylosing spondylitis with infliximab. Open Access Rheumatol (2009) 0.75
Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther (2017) 0.75
Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis. Exp Ther Med (2016) 0.75
A systematic review on the efficacy and safety of Infliximab in patients with psoriasis. Hum Vaccin Immunother (2016) 0.75
Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis. Arthritis Res Ther (2017) 0.75
Identifying a novel locus for psoriatic arthritis. Rheumatology (Oxford) (2015) 0.75
Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol (2017) 0.75
Hit hard and early: Can the march of psoriasis be halted? Indian Dermatol Online J (2013) 0.75
Case report: Infliximab treatment in two Chinese patients with psoriatic arthritis. J Zhejiang Univ Sci B (2010) 0.75
Work-related outcomes in randomised placebo-controlled pain trials: a systematic review and meta-analysis. J Occup Med Toxicol (2014) 0.75
Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Open Access Rheumatol (2009) 0.75
[Biologics]. Z Rheumatol (2016) 0.75
[Psoriatric arthritis - a permanent challenge for rheumatologists and patients: part 2: imaging diagnostics, classification and therapy]. Z Rheumatol (2011) 0.75
Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology. Curr Neurol Neurosci Rep (2017) 0.75
[Psoriatic arthritis : a permanent challenge for rheumatologists and patients--Part 1: epidemiology, pathogenesis and clinical course]. Z Rheumatol (2011) 0.75
Clinical observations programme in SpA: disease parameters, treatment options and practical management issues. Rheumatol Int (2008) 0.75
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum (1995) 15.00
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 6.49
Deoxyribonucleic acid antibody: a method to detect its primary interaction with deoxyribonucleic acid. Science (1968) 5.88
Severe psoriasis--oral therapy with a new retinoid. Dermatologica (1978) 5.67
The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol (2000) 3.62
Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol (1999) 3.60
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 3.19
Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol (1991) 2.89
Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum (2004) 2.62
Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis (2004) 2.47
Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum (1997) 2.40
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum (2005) 2.32
Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum (2001) 2.04
Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin (1996) 2.02
Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 1.85
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis (2002) 1.76
Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol (2001) 1.74
Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum (1998) 1.73
Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum (2000) 1.65
Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol (1997) 1.65
Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum (2002) 1.46
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum (2004) 1.43
Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med (1991) 1.38
Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol (2001) 1.16
An immunofluorescent method using Crithidia luciliae to detect antibodies to double-stranded DNA. Arthritis Rheum (1977) 1.09
Arthritis in psoriasis. Ann Rheum Dis (1981) 1.08
Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Derm Venereol Suppl (Stockh) (1989) 1.03
Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum (2003) 0.96
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med (2001) 5.67
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med (1977) 3.61
Discovery of a three-dimensional topological Dirac semimetal, Na3Bi. Science (2014) 3.54
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int (2016) 3.30
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 3.19
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis (2005) 2.61
Mucosal iodine staining improves endoscopic visualization of squamous dysplasia and squamous cell carcinoma of the esophagus in Linxian, China. Cancer (1998) 2.39
Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets (2006) 2.30
Psoriasis assessment tools in clinical trials. Ann Rheum Dis (2005) 2.24
Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol (1999) 2.21
Cocaine vaccines: antibody protection against relapse in a rat model. Proc Natl Acad Sci U S A (2000) 2.16
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis (2002) 2.02
Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol (2001) 1.93
The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc Natl Acad Sci U S A (2001) 1.90
A precision measurement of the mass of the top quark. Nature (2004) 1.87
Treatment recommendations for psoriatic arthritis. Ann Rheum Dis (2008) 1.85
Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol (2001) 1.76
Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis (2009) 1.70
Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A. J Appl Physiol (1985) (1997) 1.68
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Gender differences in the incidence and prevalence of patellofemoral pain syndrome. Scand J Med Sci Sports (2010) 1.65
Gene transfer in utero biologically engineers a patent ductus arteriosus in lambs by arresting fibronectin-dependent neointimal formation. Nat Med (1999) 1.64
Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res (1999) 1.62
Diagnosis of latent tuberculosis infection in bacille Calmette-Guérin vaccinated subjects in China by interferon-gamma ELISpot assay. Int J Tuberc Lung Dis (2010) 1.61
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Variants in the 5q31 cytokine gene cluster are associated with psoriasis. Genes Immun (2007) 1.59
Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis (2006) 1.59
Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum (2012) 1.58
Does hip strength analysis explain the lower incidence of hip fracture in the People's Republic of China? Bone (2004) 1.57
Measurement of the forward-backward charge asymmetry in top-quark pair production. Phys Rev Lett (2008) 1.53
Clinical features of convulsive status epilepticus: a study of 220 cases in western China. Eur J Neurol (2009) 1.53
A need for greater reporting of socioeconomic status and race in clinical trials. Ann Rheum Dis (2004) 1.52
The utility of immunologic laboratory tests in patients with rheumatic diseases. Arthritis Rheum (2001) 1.51
Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol (1997) 1.51
Site of action of cortisol in cellular immunity. J Immunol (1973) 1.46
Differential expression of Ia by murine keratinocytes and gut epithelium in response to recombinant gamma-interferon. J Invest Dermatol (1989) 1.46
Beta-globin locus activation regions: conservation of organization, structure, and function. Proc Natl Acad Sci U S A (1990) 1.46
Measurement of the W boson mass with the D0 detector. Phys Rev Lett (2012) 1.46
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol (2012) 1.46
Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem (2001) 1.45
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol (1996) 1.45
Alteration of Chlamydia trachomatis biologic behavior in synovial membranes. Suppression of surface antigen production in reactive arthritis and Reiter's syndrome. Arthritis Rheum (1995) 1.43
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis. J Rheumatol (1999) 1.40
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
Thioguanine for refractory psoriasis: a 4-year experience. J Am Acad Dermatol (2001) 1.38
alpha-Ketoacids scavenge H2O2 in vitro and in vivo and reduce menadione-induced DNA injury and cytotoxicity. Am J Physiol (1995) 1.38
Cytologic detection of esophageal squamous cell carcinoma and precursor lesions using balloon and sponge samplers in asymptomatic adults in Linxian, China. Cancer (1997) 1.35
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
The natural history of ultraviolet radiation-induced herpes simplex labialis and response to therapy with peroral and topical formulations of acyclovir. J Infect Dis (1991) 1.34
Higher blood pressure in middle-aged American adults with less education-role of multiple dietary factors: the INTERMAP study. J Hum Hypertens (2003) 1.34
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis (2002) 1.33
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis (2006) 1.32
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Cocaine catalytic antibodies: the primary importance of linker effects. Bioorg Med Chem Lett (2001) 1.31
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. J Rheumatol (1999) 1.31
Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis (2003) 1.31
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Inner cell mass-specific expression of a cell adhesion molecule (PECAM-1/CD31) in the mouse blastocyst. Dev Biol (2001) 1.27
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis (2006) 1.24
Studies of esophageal balloon cytology in Linxian, China. Cancer Epidemiol Biomarkers Prev (1997) 1.23
Genetic, structural and functional diversities of human complement components C4A and C4B and their mouse homologues, Slp and C4. Int Immunopharmacol (2001) 1.23
Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology (2008) 1.22
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum (2007) 1.21
Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA/1 mice: a model of psoriatic arthritis. Ann Rheum Dis (2004) 1.21
Search for dark matter candidates and large extra dimensions in events with a photon and missing transverse momentum in pp collision data at sqrt[s]=7 TeV with the ATLAS detector. Phys Rev Lett (2013) 1.19
The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol (2011) 1.19
Epidemiological study of hip fracture in Shenyang, People's Republic of China. Bone (1999) 1.19
Antifibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats. Acta Pharmacol Sin (2001) 1.18
Biology of Langerhans cells: selective migration of Langerhans cells into allogeneic and xenogeneic grafts on nude mice. Proc Natl Acad Sci U S A (1983) 1.18
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis (2011) 1.17
Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis (2010) 1.16
Antioxidative effects of green tea polyphenols on free radical initiated and photosensitized peroxidation of human low density lipoprotein. Chem Phys Lipids (2000) 1.15
Development and molecular cytogenetic analysis of wheat-Haynaldia villosa 6VS/6AL translocation lines specifying resistance to powdery mildew. Theor Appl Genet (1995) 1.15
Long-term maintenance of psoriatic human skin on congenitally athymic (nude) mice. J Invest Dermatol (1975) 1.14
Search for a supersymmetric partner to the top quark in final states with jets and missing transverse momentum at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.13
Isotretinoin treatment of Darier's disease. J Am Acad Dermatol (1982) 1.13
Aberrant expression of UCA1 in gastric cancer and its clinical significance. Clin Transl Oncol (2015) 1.13
A classification of psoriasis vulgaris according to phenotype. Br J Dermatol (2007) 1.13
Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res (2010) 1.12
Topical metronidazole maintains remissions of rosacea. Arch Dermatol (1998) 1.12